<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benzodiazepine withdrawal</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benzodiazepine withdrawal</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Benzodiazepine withdrawal</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">A Min Kang, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle Ruha, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3999435183"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic use of a benzodiazepine can cause physiologic dependence and the potential for a withdrawal syndrome upon rapid discontinuation. Benzodiazepine dependance can develop from use of prescribed, illicit (ie, non-prescribed use of compounds used medically), and designer (ie, compounds not used medically) agents. </p><p>The diagnosis and management of benzodiazepine withdrawal will be reviewed here. Other related topics are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>The general evaluation of delirium and confusional states and abnormal behavior in the emergency department (see  <a class="medical medical_review" href="/d/html/4824.html" rel="external">"Diagnosis of delirium and confusional states"</a> and  <a class="medical medical_review" href="/d/html/289.html" rel="external">"Evaluation of abnormal behavior in the emergency department"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The evaluation and management of benzodiazepine and other substance use disorders (see  <a class="medical medical_review" href="/d/html/88407.html" rel="external">"Benzodiazepine use disorder"</a> and  <a class="medical medical_review" href="/d/html/7807.html" rel="external">"Substance use disorders: Clinical assessment"</a> and  <a class="medical medical_review" href="/d/html/120005.html" rel="external">"Substance use disorder in adolescents: Treatment overview"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Withdrawal syndromes from other agents with sedative properties (see  <a class="medical medical_review" href="/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes"</a> and  <a class="medical medical_review" href="/d/html/105686.html" rel="external">"Opioid withdrawal: Clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6505.html" rel="external">"Opioid withdrawal in adolescents"</a> and  <a class="medical medical_review" href="/d/html/114326.html" rel="external">"Cannabis withdrawal: Epidemiology, clinical features, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/d/html/309.html" rel="external">"Gamma hydroxybutyrate (GHB) withdrawal and dependence"</a> and  <a class="medical medical_review" href="/d/html/139762.html" rel="external">"Gabapentinoid poisoning and withdrawal"</a> and  <a class="medical medical_review" href="/d/html/141081.html" rel="external">"GABA-B agonist (baclofen, phenibut) poisoning and withdrawal"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Withdrawal from sedative or analgesic started for treatment during a critical illness (see  <a class="medical medical_review" href="/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal", section on 'Discontinuation'</a>)</p><p></p><p class="headingAnchor" id="H1420060887"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Precise data on the incidence of benzodiazepine withdrawal are not available but likely reflect benzodiazepine dependence and benzodiazepine use disorder. Benzodiazepine prescriptions have been increasing in the United States over the past two decades, to an estimated 62.6 million ambulatory visits in 2015 [<a href="#rid1">1</a>]. The 2020 National Survey on Drug Use and Health in the United States indicated 4.8 million benzodiazepine misusers (in the previous year) among individuals 12 years and older [<a href="#rid2">2</a>]. The epidemiology of benzodiazepine use disorder is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/88407.html" rel="external">"Benzodiazepine use disorder", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H3229939938"><span class="h1">PATHOPHYSIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Chronic benzodiazepine use downregulates signaling through gamma aminobutyric acid (GABA) A receptors [<a href="#rid3">3</a>]. GABA is the primary inhibitory neurotransmitter in the central nervous system. As long as the benzodiazepine is present, the GABA-A receptors can provide inhibitory signaling. Upon benzodiazepine discontinuation, inhibitory signaling decreases, causing excitatory clinical manifestations. The underlying molecular processes of GABA-A receptor regulation have not been completely elucidated. The pharmacology of benzodiazepines is discussed separately. (See  <a class="medical medical_review" href="/d/html/314.html" rel="external">"Benzodiazepine poisoning", section on 'Pharmacology'</a>.)</p><p>The time to onset, severity, and duration of withdrawal are affected by pharmacokinetic parameters of the benzodiazepine that had been used. Risk factors for severe withdrawal include the following: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of an agent with short half-life or thiazole moiety</strong> – Manifestations of withdrawal from agents with shorter half-lives (eg, <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a>) begin earlier and are more severe compared with benzodiazepines with active metabolites and/or longer half-lives (eg, <a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">chlordiazepoxide</a>, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>)  (<a class="graphic graphic_table graphicRef69184" href="/d/graphic/69184.html" rel="external">table 1</a>) [<a href="#rid4">4,5</a>]. Withdrawal from alprazolam, in particular, can be difficult to treat, and manifestations do not improve following administration of other benzodiazepines in some cases [<a href="#rid6">6</a>]. Additionally, alprazolam and <a class="drug drug_general" data-topicid="10017" href="/d/drug information/10017.html" rel="external">triazolam</a> are triazolobenzodiazepines with a triazole moiety not found in other benzodiazepines, which may confer a binding affinity to a unique subset of benzodiazepine receptors and thus limit cross-reactivity [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher dose, potency, and duration or use</strong> – Chronic use of a high-potency benzodiazepine (eg, <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a>, <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a>, etizolam, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>, or <a class="drug drug_general" data-topicid="10017" href="/d/drug information/10017.html" rel="external">triazolam</a>) can lead to withdrawal manifestations that are difficult to treat with low-potency benzodiazepines (eg, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> or <a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">chlordiazepoxide</a>) at standard doses. Even though little controlled data exist on in vivo potency of designer benzodiazepines (eg, clonazolam, flubromazolam, flunitrazolam), these agents are dosed in micrograms when used recreationally and thus may need larger doses of whichever alternative benzodiazepine is used for treatment of withdrawal manifestations [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">Nonprescription sources of benzodiazepines can include substances either sold as a benzodiazepine or as unexpected additions to other street drugs. In these nonprescription sources, exposures may be to agents not available for human use in the country where the drug is found, such as etizolam, or to designer benzodiazepines such as clonazelam or flubromazolam [<a href="#rid8">8-10</a>]. For example, an illicit "Xanax bar" was found to contain flualprazolam instead of <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a> [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concurrent use or cessation of other substances or medications</strong> – This can modify the course of clinical manifestations of withdrawal and impact both diagnosis and treatment. For example, coincident withdrawal from another substance (eg, opioids) can increase the severity of manifestations and complicate the diagnosis since multiple withdrawal syndromes may contribute to the manifestations. Concurrent use of various medications or substances may delay or mask withdrawal manifestation; for example, a patient taking an alpha-2 adrenergic agonist (eg, <a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">clonidine</a>) may have blunted tachycardic or hypertensive responses after cessation of benzodiazepine use. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abrupt discontinuation after regular use</strong></p><p></p><p class="headingAnchor" id="H1778365257"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H1300654805"><span class="h2">Time course and natural history</span><span class="headingEndMark"> — </span>Withdrawal manifestations typically begin within two to three days and last 10 to 14 days or longer following cessation of benzodiazepine use [<a href="#rid12">12-14</a>]. However, these timeframes can vary depending on the specific agent. For example, withdrawal from agents with short half-lives typically begins earlier and has been reported to start as quickly as within six hours of the last dose [<a href="#rid4">4,15</a>]. Abrupt cessation of benzodiazepines after therapeutic use of as little as two weeks has been reported to cause withdrawal seizures [<a href="#rid16">16</a>]. </p><p>In a patient with mild withdrawal, manifestations will typically resolve without intervention. However, in a patient with severe withdrawal (eg, delirium, seizures), life-threatening manifestations and complications can develop unless promptly treated. Seizures can start as early as 24 hours or up to one week or longer after cessation [<a href="#rid13">13,16</a>]. (See <a class="local">'Life-threatening manifestations and complications'</a> below.)</p><p class="headingAnchor" id="H1039020438"><span class="h2">Common manifestations</span><span class="headingEndMark"> — </span>Manifestations of benzodiazepine withdrawal are similar to other sedative withdrawal syndromes but can vary based on factors such as pharmacokinetic properties of the agent. Common manifestations (ie, typically occurring in at least one-third to one-half of cases) include the following [<a href="#rid5">5,17-19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety</p><p class="bulletIndent1"><span class="glyph">●</span>Diaphoresis</p><p class="bulletIndent1"><span class="glyph">●</span>Hallucinations (with preserved sensorium) </p><p class="bulletIndent1"><span class="glyph">●</span>Headaches </p><p class="bulletIndent1"><span class="glyph">●</span>Insomnia </p><p class="bulletIndent1"><span class="glyph">●</span>Irritability </p><p class="bulletIndent1"><span class="glyph">●</span>Myalgias</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea and vomiting </p><p class="bulletIndent1"><span class="glyph">●</span>Tremor</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthermia</p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia</p><p></p><p>Signs and symptoms of the underlying disease process (eg, anxiety) may reappear and can overlap with the manifestations of the withdrawal syndrome.</p><p class="headingAnchor" id="H3223082027"><span class="h2">Life-threatening manifestations and complications</span><span class="headingEndMark"> — </span>Manifestations and complications of life-threatening benzodiazepine withdrawal include the following [<a href="#rid19">19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Agitation (53 to 100 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Psychosis (2 to 7 percent) – Can include hallucinations but also manifests delusions or bizarre behavior [<a href="#rid20">20,21</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Seizures (4 percent)</p><p></p><p>Seizures are typically generalized, tonic-clonic, isolated, and self-limited. Nonconvulsive status epilepticus can occasionally develop, most commonly reported in older adults [<a href="#rid22">22-24</a>]. (See  <a class="medical medical_review" href="/d/html/2217.html" rel="external">"Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis", section on 'Etiology'</a>.)</p><p>General complications of the hyperadrenergic state or seizures (if prolonged or multiple) can also develop if not promptly controlled. These can include volume depletion, respiratory dysfunction, hypoglycemia, rhabdomyolysis, acute kidney injury, cardiac dysfunction, cerebral edema, hepatic injury, and disseminated intravascular coagulation. (See  <a class="medical medical_review" href="/d/html/132561.html" rel="external">"Refractory status epilepticus in adults", section on 'Outcomes'</a> and  <a class="medical medical_review" href="/d/html/176.html" rel="external">"Severe nonexertional hyperthermia (classic heat stroke) in adults", section on 'Complications and sequelae'</a>.)</p><p class="headingAnchor" id="H739526867"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H2797863836"><span class="h2">History and examination</span><span class="headingEndMark"> — </span>The following are important elements of a clinical history in a patient with suspected benzodiazepine withdrawal:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms consistent with benzodiazepine withdrawal </p><p class="bulletIndent1"><span class="glyph">●</span>Duration, agent, dose, and frequency of benzodiazepine use</p><p class="bulletIndent1"><span class="glyph">●</span>Designer benzodiazepine (eg, clonazelam, flubromazolam) use obtained illicitly </p><p class="bulletIndent1"><span class="glyph">●</span>Last benzodiazepine dose</p><p class="bulletIndent1"><span class="glyph">●</span>Other medications and any recent changes</p><p class="bulletIndent1"><span class="glyph">●</span>Reason for benzodiazepine cessation or decrease in use</p><p class="bulletIndent1"><span class="glyph">●</span>Similar signs or symptoms with prior episodes of benzodiazepine cessation or dose decrease </p><p class="bulletIndent1"><span class="glyph">●</span>Indication for taking a benzodiazepine </p><p class="bulletIndent1"><span class="glyph">●</span>History of substance or alcohol use disorder</p><p class="bulletIndent1"><span class="glyph">●</span>History of seizure disorder</p><p></p><p>In a patient who is unable to provide a reliable history, previous medical records and/or state pharmacy prescription databases can be valuable sources of information. The patient may not disclose misuse of nonprescribed benzodiazepines, and these would not appear in a state pharmacy database. </p><p>A targeted physical examination should be performed to assess vital sign abnormalities, diaphoresis, mental status, airway protection, focal neurologic deficit, tremulousness, and signs of a recent seizure (eg, lateral tongue abrasions, urinary incontinence). </p><p>History and physical examination should also assess for other potential etiologies. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H4245969012"><span class="h2">Ancillary studies</span><span class="headingEndMark"> — </span>Ancillary studies are targeted towards excluding alternative etiologies since no particular study provides a definitive diagnosis of benzodiazepine withdrawal (eg, computed tomography [CT] scan of the head, thyroid function tests, lumbar puncture). Every patient with altered mental status requires a fingerstick blood glucose. </p><p>In a patient with manifestations of severe withdrawal, testing should focus on evaluating for complications (eg, creatine kinase, complete blood count, serum chemistries, blood urea nitrogen, creatinine, coagulation studies, liver enzymes, urinalysis).</p><p>Urine and serum benzodiazepine testing are generally not helpful since urine immunoassays are neither sensitive nor specific and serum testing typically has long turnaround times and does not correlate with clinical manifestations. (See  <a class="medical medical_review" href="/d/html/314.html" rel="external">"Benzodiazepine poisoning", section on 'Role of laboratory benzodiazepine testing'</a>.)</p><p class="headingAnchor" id="H1970463158"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Benzodiazepine withdrawal is a clinical diagnosis in a patient with compatible signs and symptoms (eg, tachycardia, diaphoresis, anxiety, irritability, tremors, nausea, vomiting, seizure), a history of prolonged benzodiazepine use, and a history of recent cessation or dose reduction. Similar signs or symptoms with prior episodes of benzodiazepine cessation or dose decrease suggest physiologic dependence and support the diagnosis. </p><p>In a patient with an unclear history, benzodiazepine withdrawal should be considered a diagnosis of exclusion. Non-toxicologic and other toxicologic etiologies must be ruled out, especially conditions in which diagnostic delay will hold up critical interventions and definitive care (eg, meningitis). However, presumed benzodiazepine withdrawal should still be treated during the ongoing evaluation for other causes.  </p><p class="headingAnchor" id="H2009628735"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of benzodiazepine withdrawal is similar to other hyperadrenergic states and includes other withdrawal syndromes, intoxication, drug-induced movement disorders, metabolic abnormalities, infections, and other processes. A table summarizing causes of hyperadrenergic states including unique features and diagnostic tools is provided  (<a class="graphic graphic_table graphicRef142894" href="/d/graphic/142894.html" rel="external">table 2</a>). The mnemonic FIND ME (functional [ie, psychiatric], infectious, neurologic, drugs, metabolic, endocrine) may be helpful to organize a diagnostic search for the etiology of delirium or confusion  (<a class="graphic graphic_table graphicRef59893" href="/d/graphic/59893.html" rel="external">table 3</a>), if present. (See  <a class="medical medical_review" href="/d/html/4824.html" rel="external">"Diagnosis of delirium and confusional states"</a> and  <a class="medical medical_review" href="/d/html/289.html" rel="external">"Evaluation of abnormal behavior in the emergency department"</a>.)</p><p class="headingAnchor" id="H1566381880"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>The treatment goals are to replace the pharmacologic activity of the original benzodiazepine while managing any complications, such as agitation, seizures, rhabdomyolysis, volume depletion, or acute kidney injury.  </p><p class="headingAnchor" id="H375431205"><span class="h2">All patients: Supportive care</span><span class="headingEndMark"> — </span>Standard supportive care of a patient with benzodiazepine withdrawal includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Rapidly assess and address the patient's airway, breathing, and circulation ("ABCs"). Provide supplemental oxygen as needed. Establish intravenous (IV) access in a patient with significant vital sign abnormalities, vomiting, signs of severe withdrawal, or other situations when the need for IV fluid or medications is anticipated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A postictal patient may require airway suctioning, recumbent positioning, and/or airway opening maneuvers (eg, jaw-thrust, nasal trumpet). Seizure precautions (eg, pads on the bedside rails, keeping bed at lowest position) should be instituted if the patient had a seizure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vital signs and neurological status should be checked frequently (eg, every one to two hours) and after each intervention or change in patient's status. We place a patient with severe withdrawal on a continuous cardiac and pulse oximetry monitor. A patient with sedation (possibly iatrogenic from therapy) should be placed on an end-tidal carbon dioxide (EtCO<sub>2</sub>; ie, capnography) monitor to assess for hypoventilation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Volume depletion (such as from vomiting, diaphoresis, or inadequate fluid intake) or rhabdomyolysis is treated with IV crystalloid administration. (See  <a class="medical medical_review" href="/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nausea and vomiting can be treated with an antiemetic (eg, <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a>).  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An established scoring system should be used to quantify the severity and response to interventions. We prefer the revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale  (<a class="graphic graphic_table graphicRef64835" href="/d/graphic/64835.html" rel="external">table 4</a>) (<a class="calc calc_professional" href="/d/html/13437.html" rel="external">calculator 1</a>) given its familiarity for most clinicians. Other reasonable options include the Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) and the Benzodiazepine Withdrawal Symptom Questionnaire [<a href="#rid18">18,25</a>], although we do not routinely use these. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthermia, if present, should improve with treatment of psychomotor agitation. Severe hyperthermia (generally &gt;40.5°C [105°F]) should be treated with rapid cooling (eg, immersion in ice or ice water, evaporative spray with water). (See  <a class="medical medical_review" href="/d/html/176.html" rel="external">"Severe nonexertional hyperthermia (classic heat stroke) in adults", section on 'Management'</a>.)</p><p></p><p class="headingAnchor" id="H3720603210"><span class="h2">Severe withdrawal</span><span class="headingEndMark"> — </span>We define a patient with severe withdrawal as having altered mental status (including psychosis), persistently abnormal vital signs (eg, heart rate &gt;140 beats per minute), status epilepticus, or manifestations that are refractory to treatment with a benzodiazepine. However, an established definition for severe withdrawal does not exist. </p><p>There is also no accepted benzodiazepine dose threshold for when to consider the withdrawal as refractory to benzodiazepines. This dose threshold should account for potential differences in potency between the agent being used to treat the withdrawal and the agent to which the patient originally developed tolerance. Occasionally, some patients do not improve when treated with a benzodiazepine that is different from their original agent [<a href="#rid26">26</a>]. Withdrawal manifestations from benzodiazepines with a triazole moiety (eg, <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a>) may initially appear refractory since other benzodiazepines are often less effective but improve quickly upon switching treatment to the original agent. (See <a class="local">'Pathophysiology and risk factors'</a> above.)</p><p>Severe withdrawal is commonly encountered in patients who are referred to a higher level of care after initial management attempts started in an alternate setting (eg, outpatient, substance use facility, non-critical care inpatient ward) are found to be ineffective. </p><p class="headingAnchor" id="H311680442"><span class="h3">Initial pharmacologic management</span><span class="headingEndMark"> — </span>In an adult with severe withdrawal, we start with an IV benzodiazepine. We prefer <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> 20 mg IV, but <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> 2 to 4 mg IV and <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> 2 to 5 mg IV are reasonable options. In a patient without IV access, midazolam 2 to 5 mg can be given intramuscularly (IM) until IV access is established. </p><p><a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">Diazepam</a> IV and <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> IV/IM can be re-dosed every 5 to 10 minutes, and <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> IV every 20 minutes. However, if signs and symptoms are not improving after multiple doses (instead of temporarily or partially improving as would be expected if treated with an agent with a short duration of effect or low potency), we consider the withdrawal to be refractory to benzodiazepines. </p><p class="headingAnchor" id="H2842114264"><span class="h3">Patient with benzodiazepine-refractory manifestations</span><span class="headingEndMark"> — </span>If withdrawal manifestations are being treated with a benzodiazepine that is different from the agent to which the patient originally developed tolerance, we prefer switching to the original benzodiazepine if the situation allows, particularly in the case of <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a>. This would not be feasible if the original agent was a designer illicit benzodiazepine or a benzodiazepine only available in another country.</p><p>If it is not possible to switch to the original agent or manifestations are not improving with the original agent, we suggest administering a gamma aminobutyric acid (GABA)-A receptor agonist from a separate pharmacologic class (eg, barbiturate) instead of continuing with a benzodiazepine. We prefer <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> 130 to 260 mg IV initially followed by repeat doses every 15 to 20 minutes as necessary until symptom control is achieved. Concurrent benzodiazepine administration is unnecessary since the synergistic effects with phenobarbital increase the risk of respiratory depression. Phenobarbital also increases the risk of medication interactions since it induces the cytochrome P450 enzyme system (CYP2B6, CYP3A4) and uridine diphosphate-glucuronosyltransferase (UGT)-glucuronidation, which is of particular concern in patients with opioid use disorder (ie, taking <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> or <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>) or in patients taking most forms of hormonal contraception  (<a class="graphic graphic_table graphicRef54244" href="/d/graphic/54244.html" rel="external">table 5</a>) [<a href="#rid27">27-29</a>]. </p><p>In a patient who is tracheally intubated and mechanically ventilated, we often start with <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> 10 mg/kg IV. A reasonable alternative is <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> (although withdrawal symptoms may recrudesce with cessation of infusion), which is discussed separately. (See  <a class="medical medical_review" href="/d/html/1616.html" rel="external">"Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Propofol'</a>.)</p><p>A retrospective study found <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> was effective for the management of benzodiazepine withdrawal, but a fixed-dose regimen caused sedation in one-fourth of patients [<a href="#rid30">30</a>]. There is extensive experience with phenobarbital for treating alcohol withdrawal, which is discussed separately. (See  <a class="medical medical_review" href="/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes", section on 'Refractory delirium tremens, including use of phenobarbital'</a>.)</p><p class="headingAnchor" id="H3138357983"><span class="h3">Patient with status epilepticus</span><span class="headingEndMark"> — </span>We initially treat with <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> 0.1 mg/kg IV (4 mg fixed dose, repeated if still seizing) or <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> 10 mg IM if IV access is not available. Case reports describe benzodiazepines effectively treating status epilepticus caused by benzodiazepine withdrawal [<a href="#rid22">22-24</a>]. The benefit of lorazepam over <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> and evidence of benzodiazepine efficacy for generalized convulsive status epilepticus is discussed separately. (See  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management", section on 'Benzodiazepine efficacy'</a>.)</p><p>Initial treatment with <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> 20 mg/kg IV would be a reasonable option. We would also administer phenobarbital if status epilepticus does not resolve after the initial benzodiazepine dose, although we would most likely perform rapid sequence intubation given the risk of respiratory depression in the setting of escalating GABA receptor agonist therapy. (See  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management", section on 'Second- or third-line medications'</a> and  <a class="medical medical_review" href="/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care"</a>.) </p><p class="headingAnchor" id="H3617393259"><span class="h3">Patient with psychosis</span><span class="headingEndMark"> — </span>In a patient with psychosis from benzodiazepine withdrawal, we initially treat with a benzodiazepine as described above. (See <a class="local">'Initial pharmacologic management'</a> above.)  </p><p>In addition to a benzodiazepine, we also administer an antipsychotic agent such as <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a> 5 mg IM/IV  (<a class="graphic graphic_table graphicRef60846" href="/d/graphic/60846.html" rel="external">table 6</a>) (with dose reduced by one-half in older adults). However, antipsychotic agents should not be routinely used in the treatment of benzodiazepine withdrawal and should not be administered without a benzodiazepine since they do not exhibit cross-tolerance with benzodiazepines and may also interfere with heat dissipation. (See  <a class="medical medical_review" href="/d/html/14773.html" rel="external">"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects", section on 'Administration'</a>.)</p><p>In the experience of some of our contributors, patients with psychosis from benzodiazepine withdrawal will often need <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> if they are requiring an antipsychotic agent and an IV benzodiazepine.</p><p class="headingAnchor" id="H3991810016"><span class="h2">Mild to moderate withdrawal</span><span class="headingEndMark"> — </span>A patient with normal mental status can typically be managed with an oral benzodiazepine even if they had an isolated seizure. We prefer to start with <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> 10 to 20 mg orally in the following scenarios:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient was taking an agent with a short half-life</p><p class="bulletIndent1"><span class="glyph">●</span>Desire to consolidate multiple agents to a single agent</p><p class="bulletIndent1"><span class="glyph">●</span>Patient was misusing the original agent</p><p class="bulletIndent1"><span class="glyph">●</span>The original agent was nonprescription or designer</p><p></p><p><a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">Diazepam</a> can also be given IV, but this formulation is occasionally unavailable due to drug shortages. As long as signs and symptoms are improving, we re-dose the diazepam orally every one to two hours until all signs and symptoms of withdrawal have resolved. Diazepam has active metabolites (which provide a self-taper) but should be avoided in patients with severe hepatic impairment. </p><p><a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">Lorazepam</a> (1 to 4 mg orally/IV) is a reasonable alternative and preferable in a patient with severe hepatic impairment. It can be re-dosed every 20 minutes IV and every hour orally until signs have resolved.</p><p><a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">Chlordiazepoxide</a> (25 to 50 mg orally) is another reasonable option since it has a long duration of action but should not be used in a patient with severe hepatic impairment. It can be re-dosed every hour until signs have resolved.</p><p>The original agent can also be administered to control withdrawal manifestations, which may be preferable if the patient ran out of their prescription benzodiazepine and was not misusing it.</p><p class="headingAnchor" id="H1153870153"><span class="h1">CONTINUING MANAGEMENT AND DISPOSITION</span></p><p class="headingAnchor" id="H3150319605"><span class="h2">Indications for admission</span><span class="headingEndMark"> — </span>Indications for hospital admission include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Failing an outpatient taper or treatment at an inpatient substance use program</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe withdrawal (altered mental status, psychosis, status epilepticus)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complications of withdrawal (acute kidney or liver injury, rhabdomyolysis, respiratory or cardiac dysfunction, cerebral edema, disseminated intravascular coagulation)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent uncontrolled signs and symptoms (including vital sign abnormalities and vomiting)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complicated medical or psychiatric comorbidities</p><p></p><p class="headingAnchor" id="H3926046383"><span class="h2">Tapering</span><span class="headingEndMark"> — </span>After the patient is initially stabilized, we implement a controlled process of dose reduction (ie, taper) to reduce the risk of uncontrolled withdrawal. The initial goal is to address severe withdrawal effects, if present, as described above. (See <a class="local">'Severe withdrawal'</a> above.)</p><p class="headingAnchor" id="H654120804"><span class="h3">Symptom-triggered versus scheduled</span><span class="headingEndMark"> — </span>For a patient being admitted, we continue the symptom-triggered treatment that was started in the initial stages of therapy. We administer a gamma aminobutyric acid (GABA)-A receptor agonist (eg, benzodiazepine, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>) when a patient meets the predefined threshold on an established scoring system such as the revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale  (<a class="graphic graphic_table graphicRef64835" href="/d/graphic/64835.html" rel="external">table 4</a>) (<a class="calc calc_professional" href="/d/html/13437.html" rel="external">calculator 1</a>). Evaluation intervals as frequent as every 10 to 15 minutes are appropriate for patients with more severe symptoms, followed by hourly reassessment when severe symptoms are controlled. An interval of four to six hours is reasonable for stable patients with mild symptoms receiving oral pharmacologic treatment.</p><p>If the patient's signs and symptoms are readily controlled in the emergency department, or if admitted, once signs and symptoms are controlled and pharmacologic treatment doses are decreasing, a scheduled dose reduction taper should be started, especially if the patient is being discharged. The taper can be started prior to discharge from the emergency department or hospital. A reasonable alternative in a hospitalized patient is short-term detoxification using continued symptom-triggered treatment. </p><p class="headingAnchor" id="H2953268944"><span class="h3">Taper doses and rate</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benzodiazepine taper</strong> – We administer an initial total daily taper dose that is the same or less than the total daily dose most recently received during the stabilization phase. We typically choose the same agent that was used to control the acute withdrawal manifestations. Taper reductions range from 10 to 50 percent every one to two weeks [<a href="#rid31">31</a>]. If a more rapid taper is chosen, we decrease the original dose by 25 to 50 percent every two to three days, with the greater reductions earlier in the course. The outpatient taper rate and monitoring are discussed separately. (See  <a class="medical medical_review" href="/d/html/88407.html" rel="external">"Benzodiazepine use disorder", section on 'Medically supervised taper'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phenobarbital</strong><strong> taper</strong> – In a patient who received <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> during the stabilization phase, we administer a phenobarbital taper. The maintenance doses are typically less than the dose required for initial stabilization. In an adult, we typically administer 130 to 260 mg intravenously (IV) or orally divided across two to three doses per day. In a usual taper, we then decrease the total daily dose by 10 to 20 percent every one to two days. For a more rapid taper, we decrease the total daily dose 30 to 60 mg every one to two days depending on symptoms, with a goal of finishing the taper in three to five days. We do not concurrently administer benzodiazepines given the increased risk of respiratory depression. </p><p></p><p>The taper rate depends on the patient’s capacity to tolerate withdrawal symptoms, adverse effects from the tapering agent, and the dose and duration of benzodiazepine use. The dose reductions should be adjusted based on recrudescence of intolerable withdrawal symptoms or adverse effects (eg, sedation, weakness). A taper dose should not be administered if the patient is exhibiting excess sedation or signs of intoxication (eg, slurred speech, ataxia, nystagmus).</p><p>Tapering schedules vary widely and depend on the clinical setting [<a href="#rid32">32</a>]. Longer tapers are associated with decreased withdrawal effects, increased rates of discontinuation, and lower rates of relapse even though shorter tapers may be medically safe [<a href="#rid32">32-34</a>].</p><p class="headingAnchor" id="H3582546567"><span class="h3">Outpatient taper and follow-up care</span><span class="headingEndMark"> — </span>For a patient being discharged (either from the emergency department or hospital), our decision to prescribe an outpatient taper depends on the patient's motivation to follow the taper, psychosocial factors that would preclude safe outpatient treatment, and the availability of outpatient follow-up (ideally within one week). It is important to promote outpatient follow-up (either with a substance use disorder treatment program or primary care clinician) to facilitate adjustments in the taper to individualize care. We prescribe enough medication to continue the taper through the appointment to minimize potential overuse. (See  <a class="medical medical_review" href="/d/html/88407.html" rel="external">"Benzodiazepine use disorder", section on 'Monitoring and symptom management'</a>.)</p><p>Compared with abrupt cessation, dose tapering is more effective for achieving initial cessation and maintaining sustained abstinence [<a href="#rid31">31,33,35</a>]. Especially in patients using nonprescribed benzodiazepines, completing the taper reduces the risk of relapse. Individualized dosing plans may be helpful for long-term success.</p><p class="headingAnchor" id="H3961818875"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H3823066420"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H3776730755"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114814.html" rel="external">"Society guideline links: Benzodiazepine use disorder and withdrawal"</a>.)</p><p class="headingAnchor" id="H2543239782"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for severe withdrawal</strong> – These include withdrawal from agents with shorter half-lives (especially <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a>)  (<a class="graphic graphic_table graphicRef69184" href="/d/graphic/69184.html" rel="external">table 1</a>) or higher-potency agents (especially some designer benzodiazepines), abrupt discontinuation after regular use, or concurrent use or cessation of other substances. (See <a class="local">'Pathophysiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Abrupt cessation of benzodiazepines after as little as two weeks of use has been reported to cause withdrawal symptoms beginning within two to three days and lasting 10 to 14 days or longer. Common manifestations include tachycardia, hypertension, diaphoresis, anxiety, irritability, insomnia, headaches, myalgias, tremor, nausea, and vomiting. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1">Life-threatening manifestations can include agitation, psychosis, delirium, seizures, and hyperthermia with resultant complications (eg, acute kidney injury, cardiac dysfunction, cerebral edema, hepatic injury, disseminated intravascular coagulation). Seizures are typically generalized, tonic-clonic, isolated, and self-limited, but status epilepticus can also occur. (See <a class="local">'Life-threatening manifestations and complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Ancillary studies are targeted towards excluding alternative etiologies. Every patient with altered mental status requires a fingerstick blood glucose. In a patient with manifestations of severe withdrawal, testing should focus on evaluating for complications (eg, creatine kinase, complete blood count, serum chemistries, blood urea nitrogen, creatinine, coagulation studies, liver enzymes, urinalysis). (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Benzodiazepine withdrawal is a clinical diagnosis in a patient with compatible signs and symptoms and a history of prolonged benzodiazepine use with recent cessation or dose reduction. In a patient with an unclear history, benzodiazepine withdrawal should be considered a diagnosis of exclusion. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– The goal is to replace the pharmacologic activity of the original benzodiazepine while providing supportive care and managing any complications. A patient with severe withdrawal (ie, psychosis, altered mental status, refractory to benzodiazepines, status epilepticus, persistently abnormal vital signs) may require treatment in an intensive care unit or treatment with an alternate gamma aminobutyric acid (GABA) receptor agonist (eg, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>). (See <a class="local">'Initial Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild to moderate withdrawal</strong> – A patient with normal mental status can typically be managed with an oral benzodiazepine even if they had an isolated seizure. We suggest <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>, rather than other benzodiazepines (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), owing to its active metabolites providing a self-taper. The dose is 10 to 20 mg orally but should be avoided in a patient with severe hepatic impairment. <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">Lorazepam</a> (1 to 4 mg orally/intravenously [IV]) is a reasonable alternative. (See <a class="local">'Mild to moderate withdrawal'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe withdrawal</strong> – We start with an IV benzodiazepine. We suggest <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The dose is 20 mg IV; <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> 2 to 4 mg IV and <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> 2 to 5 mg IV/intramuscularly (IM) are reasonable options. (See <a class="local">'Initial pharmacologic management'</a> above.)</p><p></p><p class="bulletIndent2">In a patient with withdrawal manifestations that are not improving after multiple benzodiazepine doses and the benzodiazepine is different from the agent to which the patient originally developed tolerance, we prefer switching to the original benzodiazepine (if possible), particularly in the case of <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a>. </p><p></p><p class="bulletIndent2">In a patient with withdrawal manifestations that are not improving after multiple benzodiazepine doses (including the originally prescribed benzodiazepine), we suggest administering <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> instead of another agent or continuing with a benzodiazepine (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We administer phenobarbital 130 to 260 mg IV followed by repeat doses every 15 to 20 minutes, if necessary, until symptom control is achieved. In a patient who is tracheally intubated and mechanically ventilated, we often start with phenobarbital 10 mg/kg IV. (See <a class="local">'Patient with benzodiazepine-refractory manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Status epilepticus</strong> – We initially treat with <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> 0.1 mg/kg IV (4 mg fixed dose, repeated if still seizing) or <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> 10 mg IM if IV access is not available. Initial treatment with <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> 20 mg/kg IV or if status epilepticus does not resolve after the initial benzodiazepine dose are reasonable options. (See <a class="local">'Patient with status epilepticus'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Psychosis</strong> – In addition to a benzodiazepine, we also administer an antipsychotic agent (eg, <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a> 5 mg IM/IV). In our experience, patients with psychosis from benzodiazepine withdrawal will often need <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>. (See <a class="local">'Patient with psychosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disposition and tapering</strong> – Indications for admission include failing an outpatient taper, severe withdrawal, complications of withdrawal, persistent vomiting, uncontrolled withdrawal signs and symptoms, and comorbidities. After the patient is stabilized, a controlled process of dose reduction (ie, taper) should be implemented, thus reducing the risk of withdrawal recrudescence and relapse. (See <a class="local">'Continuing management and disposition'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Agarwal SD, Landon BE. Patterns in Outpatient Benzodiazepine Prescribing in the United States. JAMA Netw Open 2019; 2:e187399.</a></li><li class="breakAll">Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration, 2021.</li><li><a class="nounderline abstract_t">Barnes EM Jr. Use-dependent regulation of GABAA receptors. Int Rev Neurobiol 1996; 39:53.</a></li><li><a class="nounderline abstract_t">Busto U, Sellers EM, Naranjo CA, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986; 315:854.</a></li><li><a class="nounderline abstract_t">Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990; 47:899.</a></li><li><a class="nounderline abstract_t">Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A Review of Alprazolam Use, Misuse, and Withdrawal. J Addict Med 2018; 12:4.</a></li><li><a class="nounderline abstract_t">Albeck JH. Withdrawal and detoxification from benzodiazepine dependence: a potential role for clonazepam. J Clin Psychiatry 1987; 48 Suppl:43.</a></li><li><a class="nounderline abstract_t">Zawilska JB, Wojcieszak J. An expanding world of new psychoactive substances-designer benzodiazepines. Neurotoxicology 2019; 73:8.</a></li><li><a class="nounderline abstract_t">Bollinger K, Weimer B, Heller D, et al. Benzodiazepines reported in NFLIS-Drug, 2015 to 2018. Forensic Sci Int Synerg 2021; 3:100138.</a></li><li><a class="nounderline abstract_t">Laing MK, Ti L, Marmel A, et al. An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program using point-of-care and confirmatory methods. Int J Drug Policy 2021; 93:103169.</a></li><li><a class="nounderline abstract_t">Hauck TS, Rochon S, Bahra P, Selby P. Outpatient Treatment of Chronic Designer Benzodiazepine Use: A Case Report. J Addict Med 2022; 16:e137.</a></li><li><a class="nounderline abstract_t">Basińska-Szafrańska A. Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum-benzodiazepine elimination tracking. Eur J Clin Pharmacol 2022; 78:101.</a></li><li><a class="nounderline abstract_t">HOLLISTER LE, MOTZENBECKER FP, DEGAN RO. Withdrawal reactions from chlordiazepoxide ("Librium"). Psychopharmacologia 1961; 2:63.</a></li><li><a class="nounderline abstract_t">Pétursson H. The benzodiazepine withdrawal syndrome. Addiction 1994; 89:1455.</a></li><li><a class="nounderline abstract_t">Reeves JJ, Brown AD, Collier BS. Designer benzodiazepine dependence and the difficulties of outpatient management; a case report. J Addict Dis 2024; 42:75.</a></li><li><a class="nounderline abstract_t">Fialip J, Aumaitre O, Eschalier A, et al. Benzodiazepine withdrawal seizures: analysis of 48 case reports. Clin Neuropharmacol 1987; 10:538.</a></li><li><a class="nounderline abstract_t">Petursson H, Lader MH. Withdrawal from long-term benzodiazepine treatment. Br Med J (Clin Res Ed) 1981; 283:643.</a></li><li><a class="nounderline abstract_t">Tyrer P, Murphy S, Riley P. The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord 1990; 19:53.</a></li><li><a class="nounderline abstract_t">Schöpf J. Withdrawal phenomena after long-term administration of benzodiazepines. A review of recent investigations. Pharmacopsychiatria 1983; 16:1.</a></li><li><a class="nounderline abstract_t">Dysken MW, Chan CH. Diazepam withdrawal psychosis: a case report. Am J Psychiatry 1977; 134:573.</a></li><li><a class="nounderline abstract_t">Jaffe R, Gibson E. Clonazepam withdrawal psychosis. J Clin Psychopharmacol 1986; 6:193.</a></li><li><a class="nounderline abstract_t">Kanemoto K, Miyamoto T, Abe R. Ictal catatonia as a manifestation of de novo absence status epilepticus following benzodiazepine withdrawal. Seizure 1999; 8:364.</a></li><li><a class="nounderline abstract_t">Olnes MJ, Golding A, Kaplan PW. Nonconvulsive status epilepticus resulting from benzodiazepine withdrawal. Ann Intern Med 2003; 139:956.</a></li><li><a class="nounderline abstract_t">Thomas P, Lebrun C, Chatel M. De novo absence status epilepticus as a benzodiazepine withdrawal syndrome. Epilepsia 1993; 34:355.</a></li><li><a class="nounderline abstract_t">Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol 1989; 9:412.</a></li><li><a class="nounderline abstract_t">Ashton H. Benzodiazepine withdrawal: outcome in 50 patients. Br J Addict 1987; 82:665.</a></li><li><a class="nounderline abstract_t">Sartori S, Crescioli G, Brilli V, et al. Phenobarbital use in benzodiazepine and z-drug detoxification: a single-centre 15-year observational retrospective study in clinical practice. Intern Emerg Med 2022; 17:1631.</a></li><li><a class="nounderline abstract_t">Terasaki D, Kulick B, Calcaterra S, Ray L. Phenobarbital for alcohol withdrawal in the context of the opioid epidemic: a neglected caveat. Addiction 2023; 118:1198.</a></li><li><a class="nounderline abstract_t">Bell J, Seres V, Bowron P, et al. The use of serum methadone levels in patients receiving methadone maintenance. Clin Pharmacol Ther 1988; 43:623.</a></li><li><a class="nounderline abstract_t">Kawasaki SS, Jacapraro JS, Rastegar DA. Safety and effectiveness of a fixed-dose phenobarbital protocol for inpatient benzodiazepine detoxification. J Subst Abuse Treat 2012; 43:331.</a></li><li><a class="nounderline abstract_t">Vicens C, Bejarano F, Sempere E, et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care. Br J Psychiatry 2014; 204:471.</a></li><li><a class="nounderline abstract_t">Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005; 18:249.</a></li><li><a class="nounderline abstract_t">Voshaar RC, Couvée JE, van Balkom AJ, et al. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry 2006; 189:213.</a></li><li><a class="nounderline abstract_t">Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry 1990; 47:908.</a></li><li><a class="nounderline abstract_t">Cantopher T, Olivieri S, Cleave N, Edwards JG. Chronic benzodiazepine dependence. A comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal. Br J Psychiatry 1990; 156:406.</a></li></ol></div><div id="topicVersionRevision">Topic 141183 Version 1.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30681713" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Patterns in Outpatient Benzodiazepine Prescribing in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30681713" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Patterns in Outpatient Benzodiazepine Prescribing in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8894844" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Use-dependent regulation of GABAA receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3092053" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Withdrawal reaction after long-term therapeutic use of benzodiazepines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2222129" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28777203" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A Review of Alprazolam Use, Misuse, and Withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2889723" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Withdrawal and detoxification from benzodiazepine dependence: a potential role for clonazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30802466" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : An expanding world of new psychoactive substances-designer benzodiazepines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33665593" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Benzodiazepines reported in NFLIS-Drug, 2015 to 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33627302" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program using point-of-care and confirmatory methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33900229" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Outpatient Treatment of Chronic Designer Benzodiazepine Use: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34515812" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum-benzodiazepine elimination tracking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13715373" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Withdrawal reactions from chlordiazepoxide ("Librium").</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7841856" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The benzodiazepine withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36112384" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Designer benzodiazepine dependence and the difficulties of outpatient management; a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3427560" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Benzodiazepine withdrawal seizures: analysis of 48 case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6114776" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Withdrawal from long-term benzodiazepine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1971833" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The Benzodiazepine Withdrawal Symptom Questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6131447" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Withdrawal phenomena after long-term administration of benzodiazepines. A review of recent investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/848591" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diazepam withdrawal psychosis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3711371" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clonazepam withdrawal psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10512781" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ictal catatonia as a manifestation of de novo absence status epilepticus following benzodiazepine withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14644903" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nonconvulsive status epilepticus resulting from benzodiazepine withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8384109" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : De novo absence status epilepticus as a benzodiazepine withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2574193" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A clinical scale to assess benzodiazepine withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2886145" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Benzodiazepine withdrawal: outcome in 50 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35412225" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Phenobarbital use in benzodiazepine and z-drug detoxification: a single-centre 15-year observational retrospective study in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36967706" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Phenobarbital for alcohol withdrawal in the context of the opioid epidemic: a neglected caveat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3378383" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The use of serum methadone levels in patients receiving methadone maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22285834" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety and effectiveness of a fixed-dose phenobarbital protocol for inpatient benzodiazepine detoxification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24526745" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16639148" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The diagnosis and management of benzodiazepine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16946355" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Strategies for discontinuing long-term benzodiazepine use: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2222130" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1971767" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Chronic benzodiazepine dependence. A comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
